Sign up
Pharma Capital

Diffusion Pharmaceuticals initiates pivotal phase 3 study

CEO David Kalergis from Diffusion Pharmaceuticals (NASDAQ:DFFN) tells Proactive Investors the company is using their technology to move more oxygen into oxygen-deprived tissues for cancer cells, as oxygen deprived cancer cells are three times more resistant to chemotherapy and radiation then normally oxygenated cancer cells.

Kalergis says they have opened a phase 3 study for newly diagnosed, inoperable brain cancer patients, in which they saw a fourfold increase in two year survival in their phase 2 study.

 

View full DFFN profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.